Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

Enrolling by Invitation

PHASE2Ages 1+Interventional

Autolus Limited

~500 participants

Updated 2025-08-07 on ClinicalTrials.gov

What's tested:AUTO CAR T cell therapy

At a glance

Recruiting sites

0 of 8 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapy

Measured over For up to 15 years

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

Multiple Myeloma

DLBCL

ALL, Adult and Pediatric

T Cell Lymphoma

8 sites across 4 states

United Kingdom5

Florida1

Missouri1

Texas1

This trial hasn't published a contact. View it on ClinicalTrials.gov

Incidence of Serious Adverse Events (SAE), new malignancies & adverse events of special interest (AESI) related to AUTO CAR T cell therapyFor up to 15 years
Monitoring of all SAEs / AESIs, including any new malignancy or new diagnosis of neurologic disorders, or other hematologic disorder, related to AUTO CAR T cell therapy. Monitoring of all adverse events of special interest related to AUTO CAR T cell therapy infusion.